L-Ornithine-L-aspartate in the management of hepatic encephalopathy: A meta-analysis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 1, 2009, Pages 9-14

  Jiang, Qian ^a   Jiang, Xue Hua ^a   Zheng, Ming Hua ^b   Chen, Yong Ping ^b  

^a SICHUAN UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Hepatic encephalopathy; L ornithine L aspartate; Meta analysis; Randomized controlled trial; Treatment

Indexed keywords

FRUCTOSE; LACTULOSE; ORNITHINE ASPARTATE;

AMMONIA BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEPATIC ENCEPHALOPATHY; HUMAN; META ANALYSIS; NAUSEA AND VOMITING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 58549112777     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05582.x     Document Type: Article

References (23)

1. Gitlin N. Hepatic encephalopathy. In : Zakim D, Boyer TD, eds. Hepatology. A Textbook of Liver Disease, 3rd edn, Vol. 1. Philadelphia, PA : WB Saunders Company, 1996 605 17.
2. Blei AT, Co'rdoba J, for the Practice Parameters Committee of the American College of Gastroenterology. Hepatic encephalopathy. Am. J. Gastroenterol. 2001 96 : 1968 76.
3. Shawcross D, Jalan R. Dispelling myths in the treatment of hepatic encephalopathy. Lancet 2005 365 : 431 3.
4. Riordan SM, Williams R. Treatment of hepatic encephalopathy. N. Engl. J. Med. 1997 337 : 473 9.
5. Kircheis G, Wettstein M, Dahl S, Häussinger D. Clinical efficacy of L-ornithine L-aspartate in the management of hepatic encephalopathy. Metab. Brain Dis. 2002 17 : 453 62.
6. Conn HO, Leevy CM, Vlahcevic ZR et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology. 1977 72 : 573 83.
7. Poo JL, Góngora J, Sánchez-Ávila F et al. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Ann. Hepatol. 2006 5 : 281 8.
8. Sabine S, Kircheis G, Adler G et al. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J. Hepatol. 1998 28 : 856 64.
9. Kircheis G, Nilius R, Berndt H et al. Therapeutic efficacy of L-ornithine-L-aspartate infusion concentrate in patients with liver cirrhosis and hepatic encephalopathy: a placebo-controlled double-blind study. Hepatology 1997 25 : 1351 60.
10. Abid S, Mumtaz K, Abbas Z et al. Efficacy of infusion of L-ornithine L-aspartate in cirrhotic patients with portosystemic encephalopathy: a placebo controlled study. J. Hepatol. 2005 42 (Suppl. 2 84.
11. Chen MF, Li RC, Chen CH, Gao XC. Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy. Di Yi Jun Yi Da Xue Xue Bao 2005 25 : 718 19, 722.
12. Li H. Effects of aspartate and ornithine on treatment of hepatic encephalopathy. J. Med. Forum 2006 27 : 44 5.
13. Ai J, Li XP, Song BB et al. L-ornithine-L-aspartate in the treatment of cirrhosis patients with hepatic encephalopathy. J. Mudanjiang Med. Coll. 2007 28 : 36 7.
14. Jia KL, Ma YJ, Feng SP, Fang LF, Guo YX. Controlled study of L-ornithine-L-aspartate in the treatment of cirrhosis patients with hepatic encephalopathy. Central Plains Med. J. 2006 33 : 32 3.
15. Hu Y. Observation of curative effect on treatment of cirrhosis of liver complicated by HE. Unpublished Master's Thesis of Ji Lin University, 2004-2006.
16. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin. Trial. 1996 17 : 1 12.
17. Altman DG, Schulz KF. Statistics notes: concealing treatment allocation in randomized trials. BMJ 2001 323 : 446 7.
18. Moher D, Pham B, Jones A et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998 352 : 609 13.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin. Trials 1986 7 : 177 88.
20. Ferenci P, Lockwood A, Mullen K et al. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002 35 : 716 21.
21. Blei AT, Cordoba J. Hepatic encephalopathy. Am. J. Gastroenterol. 2001 96 : 1968 76.
22. Pilar LT, Mercado RS. L-ornithine aspartate among cirrhotic patients with hepatic encephalopathy does it make a difference? Phil. J. Gastroenterol. 2006 2 : 87 94.
23. Abou-Assi S, Vlahcevic ZR. Hepatic encephalopathy: metabolic consequence of cirrhosis often is reversible. Postgrad. Med. 2001 109 : 52 70.